Ariad Pharmaceuticals, Inc. (ARIA) Announces Collaboration With Medinol Ltd., Stent Technology Leader, To Develop AP23573 Drug-Delivery Stents
10/19/2005 5:12:34 PM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 27, 2005--
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that it has entered into non-exclusive agreements with Medinol, Ltd., one of the leading cardiovascular medical device companies, to develop and commercialize stents and other medical devices to deliver ARIAD's mTOR inhibitor, AP23573, to prevent reblockage of injured vessels following stent-assisted angioplasty.
comments powered by